Raul Rabadan, PhD

Academic Appointments

  • Professor of Biomedical Informatics (in Systems Biology)

Current Administrative Positions

  • Director, Program for Mathematical Genomics Columbia Univ. and NCI Center for Topology of Cancer Evolution and Heterogeneity.
  • Co-leader, Genomics and Epigenomics Research Program, Herbert Irving Comprehensive Cancer Center
Raul Rabadan, PhD

Raul Rabadan leads a highly interdisciplinary lab with researchers from the fields of mathematics, physics, computer science, engineering, and medicine, with the common goal of solving pressing biomedical problems through quantitative computational models. The amount of high-throughput data in biological and clinical systems — from next-generation sequencing experiments to electronic health records — is increasing dramatically, allowing for the development of a quantitative understanding of these complex systems. Rabadan's lab consists of an interdisciplinary team developing mathematical and computational tools to uncover patterns of evolution in biological systems—in particular, RNA viruses and cancer.

Rabadan's scientific work has led to more than 90 peer-reviewed scientific publications, many in the highest impact factor journals in their fields, such as New England Journal of Medicine, Nature, Science, Nature Genetics, Nature Medicine, Cell, Cancer Cell, Journal of Experimental Medicine, Proceedings of Natural Academy of Sciences, and PLoS Pathogens, among others. Due to their significant implications for human health, several of Rabadan's results have been featured by the international press, including CNN, New York Times, Wall Street Journal, Associated Press, Reuters International, and The Economist. His work has led to novel therapies that are being tested in several clinical trials with extremely promising results.

He has been named one of Popular Science's Brilliant 10 (2010), a Stewart Trust Fellow (2013), and he received the Harold and Golden Lamport Award at Columbia University (2014). Raul Rabadan received his PhD in Theoretical Physics in 2001 and went on to conduct research in that field for five years at the European Laboratory for Particle Physics (CERN) in Switzerland and at the Institute for Advanced Study (IAS) at Princeton. In 2006 he joined the Systems Biology program at IAS, as a Martin A. and Helen Chooljian Member. He moved to Columbia University as an Assistant Professor in 2008, with a joint appointment in the Department of Systems Biology and the Department of Biomedical Informatics.

Departments and Divisions

  • Department of Biomedical Informatics

Centers / Institutes / Programs

  • Herbert Irving Comprehensive Cancer Center

NIH Grants

  • SINGLE-CELL CHARACTERIZATION OF TUMOR AND MICROENVIRONMENT CO-EVOLUTION IN PERIPHERAL T-CELL LYMPHOMAS (Federal Gov)

    Aug 21 2019 - Jul 31 2024

    FROM PATHOGENESIS TO NEW THERAPEUTIC TARGETS IN DIFFUSE LARGE B CELL LYMPHOMA (Federal Gov)

    Aug 4 2016 - Jul 31 2023

    ROLE OF KMT2D GENE INACTIVATION IN B CELL NON-HODGKIN LYMPHOMA (Federal Gov)

    Jul 3 2018 - Jun 30 2023

    CRCNS RESEARCH PROPOSAL: TOPOLOGICAL AND DYNAMICAL STRUCTURES OF BRAIN DEVELOPMENT AND SEXUAL-DIMORPHISM IN C. ELEGANS (Federal Gov)

    Oct 1 2019 - Sep 30 2022

    MAXIMIZING ANDROGEN DEPRIVATION IMMUNOGENICITY WITH PD-1 AND IL-8 BLOCKADE IN LETHAL PROSTATE CANCER (Private)

    Oct 11 2019 - Oct 10 2021

    CENTERS FOR CANCER SYSTEMS THERAPEUTICS (CAST) (Federal Gov)

    Aug 8 2016 - Jul 31 2021

    MSK SPORE IN LYMPHOMA-(PROJECT 4: TARGETING ACETYLTRANSFERASE GENE INACTIVATION IN DIFFUSE LARGE B CELL LYMPHOMA) (Federal Gov)

    Aug 30 2016 - Jul 31 2021

    TARGETING EPIGENETIC ADDICTIONS IN KMT2D MUTATED B CELL LYMPHOMAS (Private)

    Jul 1 2018 - Jun 30 2021

    IDENTIFICATION OF GENOMIC AND IMMUNE FACTORS IN HIGH-RISK POPULATIONS FOR PANCREATIC CANCER (Private)

    May 10 2019 - May 9 2021

    THE ROLE OF THE LZTR1 UBIQUITIN LIGASE IN STEM CELLS AND CANCER (Federal Gov)

    May 15 2015 - Apr 30 2021

    TOPOLOGY OF CANCER EVOLUTION AND HETEROGENEITY (Federal Gov)

    May 19 2015 - Apr 30 2021

    UNDERSTANDING THE ROLE OF B-RAS PROTEINS IN TUMORIGENESIS (Federal Gov)

    Mar 1 2016 - Feb 28 2021

    TCUPID-SEQ HIGH THROUGHPUT TRANSCRIPTOMIC SPATIAL MAPPING OF IMMUNE-TUMOR INTERACTIONS IN THE MICRO-ENVIRONMENT (Private)

    Jul 1 2018 - Jun 30 2020

    GENETIC CHARACTERIZATION OF OSTEOBLAST-INDUCED LEUKEMIAS (Federal Gov)

    Sep 1 2016 - Jun 30 2020

    TOPOLOGY OF CANCER EVOLUTION AND HETEROGENEITY (Federal Gov)

    May 19 2015 - Apr 30 2020

    UNCOVERING THE STRUCTURE OF EVOLUTION USING THE TOPOLOGY OF GENOMIC DATA WITH APPLICATIONS TO HIV (Federal Gov)

    Aug 3 2015 - Apr 30 2020

    THE ROLE OF THE LZTR1 UBIQUITIN LIGASE IN STEM CELLS AND CANCER (Federal Gov)

    May 15 2015 - Apr 30 2020

    THE ROLE OF THE LZTR1 UBIQUITIN LIGASE IN STEM CELLS AND CANCER (Federal Gov)

    May 15 2015 - Apr 30 2020

    TOPOLOGY OF CANCER EVOLUTION AND HETEROGENEITY (Federal Gov)

    May 19 2015 - Apr 30 2020

    QUANTITATIVE STUDIES OF INFLUENZA EVOLUTION (Federal Gov)

    Feb 1 2014 - Dec 31 2019

    DISCOVERY OF PATHOGENIC GERMLINE VARIANTS IN PEDIATRIC CANCERS USING GENOMICS. (Federal Gov)

    Sep 1 2016 - Aug 31 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    THE MECHANISMS DRIVING BRAIN ONCOGENESIS BY FGFR-TACC GENE FUSIONS (Federal Gov)

    Jul 2 2014 - May 31 2019

    COLLABORATIVE RESEARCH: RATIONAL DESIGN OF ANTICANCER DRUG COMBINATIONS USING DYNAMIC MULTIDIMENSIONAL THEORY (Federal Gov)

    Jun 15 2016 - May 31 2019

    THE MECHANISMS DRIVING BRAIN ONCOGENESIS BY FGFR-TACC GENE FUSIONS (Federal Gov)

    Jul 2 2014 - May 31 2019

    UNCOVERING THE STRUCTURE OF EVOLUTION USING THE TOPOLOGY OF GENOMIC DATA WITH APPLICATIONS TO HIV (Federal Gov)

    Aug 3 2015 - Apr 30 2019

    UNCOVERING THE STRUCTURE OF EVOLUTION USING THE TOPOLOGY OF GENOMIC DATA WITH APPLICATIONS TO HIV (Federal Gov)

    Aug 3 2015 - Apr 30 2019

    (PQB5) RECONSTRUCTION OF EVOLUTIONARY NETWORKS USING CROSS-SECTIONAL GENOMIC DATA (Federal Gov)

    Apr 1 2014 - Apr 30 2019

    THE VIROME OF MANHATTAN: A TESTBED FOR RADICALLY ADVANCING UNDERSTANDING AND FORECAST OF VIRAL RESPIRATORY INFECTIONS (Federal Gov)

    Jan 1 2016 - Mar 6 2019

    RATIONAL DESIGN OF ANTICANCER DRUG COMBINATIONS WITH DYNAMICMULTIDIMENSIONAL INPUT (Private)

    Feb 1 2016 - Feb 1 2019

    DEEP CHARACTERIZATION OF ROUSETTUS AEGYPTIACUS IMMUNE SYSTEM: USE OF BATS / NONHUMAN PRIMATES TO COMPARE IMMUNE RESPONSES DURING ASYMPTOMATIC / SYMPTOMATIC FILOVIRUS INFECTIONS (Federal Gov)

    Jan 15 2014 - Jan 14 2019

    QUANTITATIVE STUDIES OF INFLUENZA EVOLUTION (Federal Gov)

    Feb 1 2014 - Dec 31 2018

    QUANTITATIVE STUDIES OF INFLUENZA EVOLUTION (Federal Gov)

    Feb 1 2014 - Dec 31 2018

    IDENTIFICATION AND MODELING OF DRIVER GENETIC MODULES IN GLIOBLASTOMA (Federal Gov)

    Dec 10 2013 - Nov 30 2018

    POPULATION GENETIC MODELING OF VIRAL PERSIST (Private)

    Oct 1 2016 - Sep 30 2018

    COLLABORATIVE RESEARCH RATIONAL DESIGN OF ANTICANCER DRUG COMBINATIONS WITH DYNAMIC MULTIDIMENSIONAL (Private)

    Sep 1 2015 - Aug 31 2018

    EVOLUTIONARY HETEROGENEITY OF HIGH GRADE GLIOMA (Federal Gov)

    Sep 21 2016 - Aug 31 2018

    (PQB5) RECONSTRUCTION OF EVOLUTIONARY NETWORKS USING CROSS-SECTIONAL GENOMIC DATA (Federal Gov)

    Apr 1 2014 - Apr 30 2018

    (PQB5) RECONSTRUCTION OF EVOLUTIONARY NETWORKS USING CROSS-SECTIONAL GENOMIC DATA (Federal Gov)

    Apr 1 2014 - Apr 30 2018

    (PQB5) RECONSTRUCTION OF EVOLUTIONARY NETWORKS USING CROSS-SECTIONAL GENOMIC DATA (Federal Gov)

    Apr 1 2014 - Apr 30 2018

    ROLE OF MLL2 GENE INACTIVATION IN B CELL NON-HODGKIN LYMPHOMA (Federal Gov)

    Jan 1 2013 - Dec 31 2017

    ROLE OF MLL2 GENE INACTIVATION IN B CELL NON-HODGKIN LYMPHOMA (Federal Gov)

    Jan 1 2013 - Dec 31 2017

    RATIONAL DESIGN OF ANTICANCER DRUG COMBINATIONS WITH DYNAMIC MULTIDIMENSIONAL INPUT (Private)

    Sep 1 2015 - Aug 31 2017

    LONG NON-CODING RNAS IN DIABETES (Private)

    Jun 1 2014 - May 31 2017

    ROLE OF ACETYLTRANSFERASE GENE INACTIVATION IN FOLLICULAR LYMPHOMA PATHOGENESIS (Federal Gov)

    Apr 1 2012 - Mar 31 2017

    ROLE OF ACETYLTRANSFERASE GENE INACTIVATION IN FOLLICULAR LYMPHOMA PATHOGENESIS (Federal Gov)

    Apr 1 2012 - Mar 31 2017

    ROLE OF ACETYLTRANSFERASE GENE INACTIVATION IN FOLLICULAR LYMPHOMA PATHOGENESIS (Federal Gov)

    Apr 1 2012 - Mar 31 2017

    NATIONAL CENTER: MULTISCALE ANALYSIS OF GENOMIC AND CELLULAR NETWORKS (MAGNET) (Federal Gov)

    Sep 26 2005 - Jul 31 2016

    TRANSCRIPTOME ANNOTATION OF INFECTIOUS AGENTS HOST SPECIES USING HIGH THROUGHPUT GENOMIC DATA (Federal Gov)

    Feb 20 2013 - Feb 19 2016

    CLONAL EVOLUTION AND CHEMOTHERAPY RESISTANCE IN ALL (Private)

    Jan 1 2014 - Dec 31 2015

    THE GENETICS OF PERIPHERAL T-CELL LYMPHOMAS (Private)

    Oct 1 2011 - Sep 30 2014

    ROLE OF METHYLTRANSFERASE GENE INACTIVATION IN DIFFUSE LARGE B CELL LYMPHOMA (Private)

    Aug 1 2012 - Jul 31 2014

    CONTE CENTER FOR COMPUTATIONAL SYSTEMS GENOMICS OF NEUROPSYCHIATRIC PHENOTYPES (Federal Gov)

    Sep 22 2011 - Jul 31 2014

    STEWART TRUST PILOT AWARDS FOR FY12-13 (YEAR 14) (Private)

    Jul 1 2012 - Jun 30 2014

    TRANSLATIONAL RESEARCH IN ALCOHOLIC HEPATITUS (Federal Gov)

    Jun 1 2013 - May 31 2014

    TARGETING GENETIC AND METABOLIC NETWORKS IN T-ALL (Private)

    Jun 1 2011 - May 31 2014

    ANALYSIS OF POPULATION GENOMICS OF PATHOGENS (Private)

    Jan 1 2012 - Dec 31 2012

    INTEGRATED DISCOVERY AND HYPOTHESIS TESTING OF NEW ASSOCIATI ONS IN RARE DISEASES (Federal Gov)

    Jul 1 2009 - Jun 30 2012